SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company, which develops innovative surgical robotic technologies, also saw its first-half revenue reach $25.0 million, up 65.6% from $15.1 million in the first half of 2025. These results reflect the continued momentum behind the SSi Mantra surgical robotic system, which is gaining traction in multiple markets.
During the quarter, SS Innovations installed 30 new SSi Mantra systems, a 30.4% increase compared to the prior-year period. The total installed base now stands at 224 systems across 12 countries, with cumulative surgeries performed exceeding 12,272. This growth in installations is the primary driver of the company's commercial success, as each system generates recurring revenue through service and procedure-related sales.
The financial performance also highlighted a gross profit of $7.1 million for the quarter, up 20.0% year over year, though gross margin declined to 50.9% from 59.1%. For the first half, gross profit increased 77.5% to $12.4 million, with an improved gross margin compared to the prior-year period. The margin fluctuation is attributed to product mix and investments in scaling operations.
Looking ahead, regulatory milestones are expected to be significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to the U.S. and European markets, which are among the largest for surgical robotics. The company's telesurgery achievements are also expanding the clinical profile of the SSi Mantra, demonstrating its capabilities beyond traditional settings.
The strong revenue growth and expanding installed base signal robust demand for the SSi Mantra platform, which competes with established players like Intuitive Surgical's da Vinci system. SS Innovations' focus on affordability and accessibility, particularly in emerging markets, positions it to capitalize on the growing adoption of minimally invasive surgery globally. As the company continues to execute on its strategic priorities, the positive trajectory in revenue and system utilization is likely to attract investor attention.
For more information on SS Innovations' latest news, visit their newsroom at https://nnw.fm/SSII.
